Stock Track | RemeGen Plummets 5.42% Intraday Amid US-China Biotech Regulatory Pressures

Stock Track06-02

RemeGen's stock plummeted 5.42% intraday on Tuesday, extending recent declines as the biotechnology sector faces intensified regulatory headwinds between the United States and China.

The decline comes as US legislators have proposed incorporating biotechnology into the COINS Act's regulatory scope, which would restrict American capital flows into Chinese innovative pharmaceutical companies. Simultaneously, market rumors suggest Chinese regulators may impose pre-approval requirements on overseas business development transactions for domestic drug developers.

These dual-sided regulatory barriers directly undermine the core valuation logic for the sector's internationalization thesis. The broader biotechnology sector is experiencing significant selling pressure, with several peers also declining sharply during the session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1109642595?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 09:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109642595","market":"hk","top_or_hot":-1,"title":"Stock Track | RemeGen Plummets 5.42% Intraday Amid US-China Biotech Regulatory Pressures","media":"Stock Track","content":"<p>RemeGen's stock plummeted 5.42% intraday on Tuesday, extending recent declines as the biotechnology sector faces intensified regulatory headwinds between the United States and China.</p><p>The decline comes as US legislators have proposed incorporating biotechnology into the COINS Act's regulatory scope, which would restrict American capital flows into Chinese innovative pharmaceutical companies. Simultaneously, market rumors suggest Chinese regulators may impose pre-approval requirements on overseas business development transactions for domestic drug developers.</p><p>These dual-sided regulatory barriers directly undermine the core valuation logic for the sector's internationalization thesis. The broader biotechnology sector is experiencing significant selling pressure, with several peers also declining sharply during the session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | RemeGen Plummets 5.42% Intraday Amid US-China Biotech Regulatory Pressures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | RemeGen Plummets 5.42% Intraday Amid US-China Biotech Regulatory Pressures\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-02 09:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>RemeGen's stock plummeted 5.42% intraday on Tuesday, extending recent declines as the biotechnology sector faces intensified regulatory headwinds between the United States and China.</p><p>The decline comes as US legislators have proposed incorporating biotechnology into the COINS Act's regulatory scope, which would restrict American capital flows into Chinese innovative pharmaceutical companies. Simultaneously, market rumors suggest Chinese regulators may impose pre-approval requirements on overseas business development transactions for domestic drug developers.</p><p>These dual-sided regulatory barriers directly undermine the core valuation logic for the sector's internationalization thesis. The broader biotechnology sector is experiencing significant selling pressure, with several peers also declining sharply during the session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1109642595","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109642595","pubTimestamp":1780365215,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"RemeGen's stock plummeted 5.42% intraday on Tuesday, extending recent declines as the biotechnology sector faces intensified regulatory headwinds between the United States and China.The decline comes...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"个股追踪|美中生物科技监管压力下RemeGen盘中暴跌5.42%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"RemeGen's stock plummeted 5.42% intraday on Tuesday, extending recent declines as the biotechnology sector faces intensified regulatory headwinds between the United States and China.The decline comes as US legislators have proposed incorporating biotechnology into the COINS Act's regulatory scope, which would restrict American capital flows into Chinese innovative pharmaceutical companies. Simultaneously, market rumors suggest Chinese regulators may impose pre-approval requirements on overseas business development transactions for domestic drug developers.These dual-sided regulatory barriers directly undermine the core valuation logic for the sector's internationalization thesis. The broader biotechnology sector is experiencing significant selling pressure, with several peers also declining sharply during the session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109642595","isCrawlerRequest":true}